Maleimide constrained BAD BH3 domain peptides as BCL-xL Inhibitors: A Versatile Approach to Rapidly Identify Sites Compatible with Peptide Constraining. Bioorg. Med. Chem. Lett., 87, 129260.
Rational Design of Harakiri (HRK)-Derived Constrained Peptides as BCL-xL inhibitors. Chem. Commun., DOI: 10.1039/D2CC06029A
α-Helix stabilization by co-operative side chain charge-reinforced interactions to phosphoserine in a basic kinase-substrate motif. Biochem J, 479 (5), 687–700